Printer Friendly
The Free Library
7,774,290 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ERGOLOID MESYLA.TES (HYDERGINE).


MODE OF ACTION

Mechanism is unclear, but may improve cerebral blood flow.

EFFECTS ON ALZHEIMER'S DISEASE

May have modest benefits in a variety of age-related mental impairment.

CONTRAINDICATIONS

Known hypersensitivity to ergoloid mesylates.

Acute or chronic psychosis.

Pregnancy Category D.

ADVERSE EFFECTS

Gastrointestinal adverse effects, such as nausea.

DRUG-DRUG INTERACTIONS

Delavirdine delavirdine /del·a·vir·dine/ (del?ah-vir´den) an antiretroviral, inhibiting reverse transcriptase; used as the mesylate salt in the treatment of HIV infection.

del·a·vir·dine
n.
 (Rescriptor), indinavir (Crixivan), nelfinavir nelfinavir /nel·fin·a·vir/ (nel-fin´ah-vir) an HIV protease inhibitor that causes formation of immature, noninfectious viral particles; used as the mesylate salt in the treatment of HIV infection.  (Viracept), saquinavir (Fortovase), and efavirenz (Sustiva) may increase ergot ergot (ûr`gət), disease of rye and other cereals caused by the fungus Claviceps purpurea. The cottony, matlike body, or mycelium, of the fungus develops in the ovaries of the host plant; it eventually turns into a hard pink or purple  levels resulting in ergotism ergotism /er·got·ism/ (er´go-tizm) chronic poisoning produced by ingestion of ergot, marked by cerebrospinal symptoms, spasms, cramps, or by a kind of dry gangrene.

er·got·ism
n.
 (nausea, vomiting, and vasospastic ischemia).

Ergoloid mesylates should NEVER be given with naratriptan (Amerge), rizatriptan (Maxalt), or zolmitriptan zolmitriptan /zol·mi·trip·tan/ (zol?mi-trip´tan) a selective serotonin receptor agonist used to relieve acute migraine.

zol·mi·trip·tan
n.
 (Zomig) due to the potential for vasospastic reactions.

RECOMMENDED DOSE

Initial dose is 1 mg three times a day.

May titrate ti·trate
v.
To determine the concentration of a solution by titration or perform the operation of titration.



ti
 up to 12 mg/day, although 6 mg/day is usually an effective dose.

May take up to 6 months before efficacy can be determined.

DOSAGE FORMS AVAILABLE

Oral tablets: 0.5 mg and 1 mg.

Sublingual tablets: 0.5 mg and 1 mg.

Liquid capsule: 1 mg.

Liquid: 1 mg/ml.

MANUFACTURER

Rugby, Sandoz, and various generic companies.

OTHER POINTS OF INTEREST

Sublingual tablets should not be crushed or chewed.

This therapy is rarely used.

References

(1.) Hutchison TA, Shahan DR, Anderson ML (Eds): DRUGDEX System. MICROMEDEX, Inc., Englewood, Colorado (Edition expires 12/2000).

(2.) Hebel SK. Katstrup EK (Eds): Drug Facts and Comparisons. St. Louis, MO (2001).
COPYRIGHT 2001 Southern Medical Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Author:SLAGLE, MARK A.
Publication:Southern Medical Journal
Article Type:Brief Article
Date:Jul 1, 2001
Words:216
Previous Article:GINKGO BILOBA.(Brief Article)
Next Article:Selected Ongoing Clinical Trials [*].
Topics:



Related Articles
Tower has a ball with energy conservation. (downtown Los Angeles highrise, 801 Tower, incorporates thermal energy storage technology into its cooling...
A pollutant that can alter growth. (Bisephenol A)(Brief Article)
No Comment.(current events analysis)(Brief Article)
Superconducting detector array successfully deployed through NIST collaboration. (News Briefs).(Brief Article)
NIST researchers model anti-reflection structures for photon number resolving optical detectors.(News Briefs)
NIST photon number resolving detectors contribute to quantum key distribution.(News Briefs)
Judith K. Stoleson: The Entrepreneur's Source.(The Nominees--2006)(Brief article)
Data provider negotiating with building owners.(Property Management)
Two new titles from Elsevier.(Elsevier Science & Health )(Brief article)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles